Many studies have shown that intensive lipid-lowering therapy with a high dose of statins or a combination of statins with ezetimibe/proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors prevents recurrent stroke after transient ischemic attack and ischemic stroke. Here, PCSK9 is linked to transient ischemic attack.